Ectin Research AB Logo

Ectin Research AB

ECTIN B | SPGR

Overview

Corporate Details

ISIN(s):
SE0015987706 (+1 more)
LEI:
549300IDDKUG9RWXFN04
Country:
Sweden
Address:
c/o Walthon Advokater, 102 43 Stockholm
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ectin Research AB is a clinical-stage pharmaceutical company focused on the research and development of novel treatments for cancer. The company's primary drug candidate, MFA-370, is a therapy being developed to eliminate cancerous tumors. The initial focus for clinical trials of MFA-370 is the treatment of metastatic bladder cancer. Ectin Research's objective is to commercialize its projects and knowledge derived from its research in medicine and biotechnology to diagnose and treat various forms of cancer.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ectin Research AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ectin Research AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ectin Research AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medicofarma Biotech Spolka Akcyjna Logo
Biotech R&D firm developing novel drugs, devices, and therapies with a focus on oncology.
Poland MDB
Medigene AG Logo
An immuno-oncology platform creating T cell receptor (TCR)-guided therapies to treat cancer.
Germany MDG1
MedinCell S.A. Logo
Develops and licenses long-acting injectable therapies using proprietary technology.
France MEDCL
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Mendus Logo
Developing immunotherapies using dendritic cells to prevent recurrence of AML & ovarian cancer.
Sweden IMMU
Merck KGaA Logo United States of America 6MK
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Modus Therapeutics Holding AB Logo
Clinical-stage biotech developing sevuparin for sepsis, septic shock, and inflammation.
Sweden MODTX
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN